Macrocyclic Chelators for Rapid Radiometal Complexation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bifunctional ligands for radiopharmaceutical applications, such as in radioimmunotherapy and positron emission tomography, face challenges with slow kinetics and low in vivo stability, limiting their effectiveness for targeted cancer imaging and therapy.
Innovation Solution
Development of new chelating agents and multifunctional ligands that enhance complexation kinetics and stability in human serum, allowing for rapid and stable binding of biologically important metals, including cytotoxic activity against cancer cells without removing Zn(II), and suitable for applications in radiotherapy, decorporation of radionuclides, and imaging modalities like MRI and PET.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If currently available bifunctional ligands (C-DOTA and C-DTPA analogues) are used for radiopharmaceutical applications, then the ligands can bind radionuclides, but the complexation kinetics are slow and in vivo stability is low
Solution Approach 1:
The patent modifies the chemical structure of chelating agents by changing parameters such as the macrocyclic ring structure (using 1,4,7,10-tazacyclododecane-1,4,7-triacetic acid backbone instead of traditional DOTA/DTPA), adjusting denticity (5-, 6-, or 8-dentate configurations), and modifying functional groups to achieve both rapid complexation kinetics and high in vivo stability simultaneously
Solution Approach 2:
The invention creates composite chelating structures that combine multiple functional elements: a macrocyclic core with multiple acetic acid arms, additional coordinating groups, and bifunctional linkers for biomolecule conjugation. This composite approach enables the chelator to achieve both fast kinetics and high stability that single-structure ligands cannot provide
2Speed
If DTPA is used as a decorporation agent for radionuclides, then rapid complexation kinetics are achieved, but binding selectivity is low and zinc stripping occurs
Solution Approach 1:
The patent introduces specific local structural features to the chelating agent, including a macrocyclic cavity with specific geometry and pre-organized coordinating atoms positioned to match the ionic radius and coordination preferences of target radionuclides. This local structural optimization provides high selectivity for actinides and lanthanides while avoiding zinc binding, eliminating the zinc stripping problem associated with DTPA
3Reliability
If Gd(DTPA) and Gd(DOTA) are used as MRI contrast agents, then the agents provide extracellular distribution, but the relaxivity is low and tissue specificity is poor
Solution Approach 1:
The patent designs multifunctional chelating agents that can serve multiple purposes: they function as MRI contrast agents through paramagnetic metal complexation, as targeting vectors through conjugation to biomolecules like antibodies and peptides, and as theranostic platforms combining imaging and therapy capabilities. This multi-functionality allows a single chelator structure to achieve both stability and high tissue specificity through targeted delivery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new chelating agents provide enhanced stability and kinetic performance, enabling effective targeted imaging and therapy with reduced toxicity and improved tissue specificity, and are suitable for various biomedical and environmental applications.
Implementation Method 1
Macrocyclic and acyclic chelating agents have been employed for biomedical, environmental, and radiopharmaceutical applications
Data Source
AI summary
Multifunctional chelators, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders.